220 related articles for article (PubMed ID: 12963485)
1. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
2. Chalcone inhibition of anthracycline secondary alcohol metabolite formation in rabbit and human heart cytosol.
Silvestrini A; Meucci E; Vitali A; Giardina B; Mordente A
Chem Res Toxicol; 2006 Nov; 19(11):1518-24. PubMed ID: 17112240
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
Licata S; Saponiero A; Mordente A; Minotti G
Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
[TBL] [Abstract][Full Text] [Related]
4. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
6. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
8. Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.
Takahashi RH; Bains OS; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 Jun; 36(6):991-4. PubMed ID: 18322072
[TBL] [Abstract][Full Text] [Related]
9. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
10. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
11. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
[TBL] [Abstract][Full Text] [Related]
12. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.
Hintzpeter J; Seliger JM; Hofman J; Martin HJ; Wsol V; Maser E
Toxicol Appl Pharmacol; 2016 Feb; 293():21-9. PubMed ID: 26773812
[TBL] [Abstract][Full Text] [Related]
14. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE
J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598
[TBL] [Abstract][Full Text] [Related]
15. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
16. Understanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methods.
Pirolli D; Giardina B; Mordente A; Ficarra S; De Rosa MC
Eur J Med Chem; 2012 Oct; 56():145-54. PubMed ID: 22982121
[TBL] [Abstract][Full Text] [Related]
17. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
18. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium.
Minotti G; Recalcati S; Mordente A; Liberi G; Calafiore AM; Mancuso C; Preziosi P; Cairo G
FASEB J; 1998 May; 12(7):541-52. PubMed ID: 9576481
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs.
Mordente A; Silvestrini A; Martorana GE; Tavian D; Meucci E
Drug Metab Dispos; 2015 Nov; 43(11):1691-701. PubMed ID: 26265744
[TBL] [Abstract][Full Text] [Related]
20. Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Hoefer CC; Blair RH; Blanco JG
J Pharm Sci; 2016 Jun; 105(6):2005-2008. PubMed ID: 27112290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]